Andrew Blauvelt
Expertise in
6
conditions

Dr. Andrew Blauvelt

Dermatology
James W. Baker MD LLC
9495 SW Locust St Ste A, 
Portland, OR 
Expertise in
6
conditions
James W. Baker MD LLC
9495 SW Locust St Ste A, 
Portland, OR 

Overview

Andrew Blauvelt is a Dermatologist in Portland, Oregon. Dr. Blauvelt is highly rated in 6 conditions, according to our data. His top areas of expertise are Plaque Psoriasis, Psoriasis, Atopic Dermatitis, and Actinic Keratosis.

His clinical research consists of co-authoring 314 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Dermatology

Licenses

Dermatology in OR

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Moda Health
  • EPO
  • PPO

Locations

James W. Baker MD LLC
9495 SW Locust St Ste A, Portland, OR 97223

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Decreasing Resident Memory T Cells While Increasing Clinical Durability: Higher Induction Doses of Risankizumab for Moderate-to-severe Plaque Psoriasis
Decreasing Resident Memory T Cells While Increasing Clinical Durability: Higher Induction Doses of Risankizumab for Moderate-to-severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: October 24, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 30, 2022
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis
A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis
Enrollment Status: Completed
Publish Date: November 10, 2022
Intervention Type: Drug
Study Drug: Apremilast
Study Phase: Phase 4
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Other, Biological
Study Drugs: Lebrikizumab, Topical Corticosteroid
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Enrollment Status: Completed
Publish Date: September 25, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Enrollment Status: Completed
Publish Date: June 04, 2019
Intervention Type: Other, Biological
Study Phase: Phase 2
View 11 Less Clinical Trials

314 Total Publications

Moderate-to-severe atopic dermatitis and systemic corticosteroids are associated with insulin resistance and metabolic syndrome.
Moderate-to-severe atopic dermatitis and systemic corticosteroids are associated with insulin resistance and metabolic syndrome.
Journal: JAAD international
Published: December 16, 2025
Similar Doctors
Expertise in
19
conditions
Dr. Alex Ortega
Dermatology
Expertise in
19
conditions
Dr. Alex Ortega
Dermatology

University Andrology Lab LLC

3303 S Bond Ave, 
Portland, OR 
 (6.1 miles away)
503-418-3376
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alex Ortega is a Dermatologist in Portland, Oregon. Dr. Ortega is highly rated in 19 conditions, according to our data. His top areas of expertise are Pyoderma Gangrenosum, Pityriasis Rubra Pilaris, Calciphylaxis, and Psoriasis.

Expertise in
12
conditions
Dr. Teri Greiling
Dermatology
Expertise in
12
conditions
Dr. Teri Greiling
Dermatology

University Andrology Lab LLC

3303 S Bond Ave, 
Portland, OR 
 (6.1 miles away)
503-418-3376
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Teri Greiling is a Dermatologist in Portland, Oregon. Dr. Greiling is highly rated in 12 conditions, according to our data. Her top areas of expertise are Pityriasis Rubra Pilaris, Acrokeratoelastoidosis of Costa, Palmoplantar Keratoderma, and Cicatricial Pemphigoid.

Expertise in
12
conditions
Dr. Eric Simpson
Dermatology
Expertise in
12
conditions
Dr. Eric Simpson
Dermatology

Oregon Health & Science University

3303 S Bond Ave, 
Portland, OR 
 (6.1 miles away)
503-418-3376
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eric Simpson is a Dermatologist in Portland, Oregon. Dr. Simpson is highly rated in 12 conditions, according to our data. His top areas of expertise are Atopic Dermatitis, Psoriasis, Plaque Psoriasis, and Actinic Keratosis.

Frequently Asked Questions about Dr. Andrew Blauvelt

How do I make an appointment with Dr. Andrew Blauvelt?

You can book an appointment with Dr. Andrew Blauvelt by calling their office at 503-445-2200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Andrew Blauvelt a top-rated expert for Plaque Psoriasis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Andrew Blauvelt is classified as an Elite expert for Plaque Psoriasis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Andrew Blauvelt specialize in?

While Dr. Andrew Blauvelt is a Dermatology, they have specific expertise in Plaque Psoriasis, Psoriasis, and Atopic Dermatitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Andrew Blauvelt participate in research or clinical trials?

Yes. Dr. Andrew Blauvelt has published 314 articles and abstracts on conditions like Plaque Psoriasis. You can view a list of Dr. Andrew Blauvelt's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Andrew Blauvelt accept my insurance?

Dr. Andrew Blauvelt accepts most major insurance plans, including Cambia Health Solutions and Moda Health. We recommend calling the office directly at 503-445-2200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Blauvelt's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile